Tracking the long-term safety and effectiveness of biologic and targeted synthetic therapies for psoriatic arthritis (PsA).
The Psoriatic Arthritis Register (BSR-PsA) tracks the long-term safety, effectiveness and outcomes of biologic and targeted synthetic therapies for people with psoriatic arthritis (PsA).
Established in 2018 and run by the University of Aberdeen on behalf of the British Society for Rheumatology, the register collects long-term data to improve understanding of PsA, treatment outcomes and patient experience.
The register aims to improve understanding of the long-term impact of PsA on quality of life, work and daily functioning, while monitoring the safety of treatments. It also supports research into the factors that influence treatment response, helping to advance more personalised care for people with PsA.
BSR and the University of Aberdeen welcome applications to use BSR-PsA data for clinical and research projects. The registers team can support researchers in developing and delivering studies that improve understanding of PsA and improve patient care.
If you're an NHS clinician, health professional or research network staff with a recruitment query about a patient or the treatment cohorts in PsA, please get in touch.